Severity
Moderate
FDA Drug recall · Reported March 6, 2024
Subpotent Drug: Out of specification for assay
Bausch Health Companies, Inc. recalled Omeprazole and Sodium Bicarbonate For Oral Suspension 40mg/1,680mg, This packet contains… - a moderate-severity action.
Omeprazole and Sodium Bicarbonate For Oral Suspension 40mg/1,680mg, This packet contains… was recalled by Bausch Health Companies, Inc. in March 6, 2024. Reason: Subpotent Drug: Out of specification for assay. Check the official notice for the remedy. Verify recall #D-0355-2024 with the FDA Drug before acting.
The recall
Bausch Health Companies, Inc. issued this moderate-severity FDA Drug recall-Subpotent Drug: Out of specification for assay.
Sourced from official FDA Drug enforcement records. Verify recall #D-0355-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0355-2024) was formally reported on March 6, 2024, with the manufacturer initiating the action on February 2, 2024. It is classified under Moderate severity (Class II), with a current status of Completed. Bausch Health Companies, Inc. is listed as the recalling firm, operating out of Bridgewater, NJ. Federal records list the affected scope as 3,600 cartons.
The documented reason for this recall is: Subpotent Drug: Out of specification for assay Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
3,600 cartons
Related Recalls
6
5 from same agency
Omeprazole and Sodium Bicarbonate For Oral Suspension 40mg/1,680mg, This packet contains 40mg of omeprazole and 1,680mg of sodium bicarbonate, Directions for Use: Empty packet contents into a small cup containing 1 to 2 tablespoons of WATER. DO NOT USE OTHER LIQUIDS OR FOODS. Stir well and drink immediately. Rx Only, Distributed by: Oceanside Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ 08807, NDC 68682-991-30.
Subpotent Drug: Out of specification for assay
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Completed |
| Recall number | D-0355-2024 |
| Date reported | March 6, 2024 |
| Date initiated | February 2, 2024 |
| Recalling firm | Bausch Health Companies, Inc. |
| Firm location | Bridgewater, NJ |
| Affected scope | 3,600 cartons |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 6, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.